Advertisement
CCXI vs IPHA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CCXI is a Buy and IPHA is a Hold.
CCXI's Stochastic Oscillator remains in oversold zone for 11 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CCXI's RSI Oscillator exited the oversold zone, 7 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
Following a +3.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCXI advanced for three days, in 58 of 83 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CCXI as a result. In 12 of 24 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 50%.
The Moving Average Convergence Divergence Histogram (MACD) for CCXI turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In 6 of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCXI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CCXI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. CCXI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.131) is normal, around the industry mean (-542.660). P/E Ratio (-5.431) is within average values for comparable stocks, (117.432). Projected Growth (PEG Ratio) (2.600) is also within normal values, averaging (15.932). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. CCXI's P/S Ratio (0.000) is very low in comparison to the industry average of (3.158).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCXI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
IPHA's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for IPHA moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 21 of the 24 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 78 cases where IPHA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on IPHA as a result. In 92 of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on October 20, 2026. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Following a +10.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in 148 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
IPHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
IPHA moved below its 50-day moving average on September 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IPHA crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for IPHA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.164) is normal, around the industry mean (2.973). P/E Ratio (-2.961) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (55.556) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IPHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CCXI | IPHA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 64 | 62 | |
P/E GROWTH RATING 1..100 | 17 | 27 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IPHA's Valuation (18) in the null industry is significantly better than the same rating for CCXI (96) in the Biotechnology industry. This means that IPHA’s stock grew significantly faster than CCXI’s over the last 12 months.
IPHA's Profit vs Risk Rating (100) in the null industry is in the same range as CCXI (100) in the Biotechnology industry. This means that IPHA’s stock grew similarly to CCXI’s over the last 12 months.
IPHA's SMR Rating (98) in the null industry is in the same range as CCXI (98) in the Biotechnology industry. This means that IPHA’s stock grew similarly to CCXI’s over the last 12 months.
IPHA's Price Growth Rating (62) in the null industry is in the same range as CCXI (64) in the Biotechnology industry. This means that IPHA’s stock grew similarly to CCXI’s over the last 12 months.
CCXI's P/E Growth Rating (17) in the Biotechnology industry is in the same range as IPHA (27) in the null industry. This means that CCXI’s stock grew similarly to IPHA’s over the last 12 months.
| CCXI | IPHA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 86% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 50% | 1 day ago 81% |
| MACD ODDS (%) | 1 day ago 75% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 65% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 84% |
| Advances ODDS (%) | 18 days ago 70% | 3 days ago 74% |
| Declines ODDS (%) | 1 day ago 81% | 1 day ago 85% |
| BollingerBands ODDS (%) | N/A | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 76% | 1 day ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CCXI’s FA Score shows that 1 FA rating(s) are green while IPHA’s FA Score has 2 green FA rating(s).
- CCXI’s FA Score: 1 green, 4 red.
- IPHA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CCXI’s TA Score shows that 3 TA indicator(s) are bullish while IPHA’s TA Score has 6 bullish TA indicator(s).
- CCXI’s TA Score: 3 bullish, 4 bearish.
- IPHA’s TA Score: 6 bullish, 4 bearish.
Price Growth
CCXI (@Financial Conglomerates) experienced а -4.43% price change this week, while IPHA (@Biotechnology) price change was +9.79% for the same time period.
The average weekly price growth across all stocks in the @Financial Conglomerates industry was -0.29%. For the same industry, the average monthly price growth was -0.79%, and the average quarterly price growth was +1.41%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
IPHA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Financial Conglomerates (-0.29% weekly)Financial conglomerates usually encompass a wide range of financial services including (not necessarily limited to) investment banking, insurance, capital raising/underwriting, trading of financial securities, investment advisory services, wealth management of high net-worth individuals, and retail banking. Think Citigroup, American Express Company, ING Group.
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CCXI and
Correlation & Price change
A.I.dvisor indicates that over the last year, CCXI has been loosely correlated with SPRO. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CCXI jumps, then SPRO could also see price increases.
| Ticker / NAME | Correlation To CCXI | 1D Price Change % | ||
|---|---|---|---|---|
| CCXI | 100% | -0.82% | ||
| SPRO - CCXI | 48% Loosely correlated | -3.42% | ||
| ABOS - CCXI | 48% Loosely correlated | +1.48% | ||
| ANVS - CCXI | 34% Loosely correlated | -0.15% | ||
| IPHA - CCXI | 34% Loosely correlated | -3.82% | ||
| IDYA - CCXI | 34% Loosely correlated | +1.83% | ||
More | ||||
IPHA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IPHA has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IPHA jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To IPHA | 1D Price Change % | ||
|---|---|---|---|---|
| IPHA | 100% | -3.82% | ||
| MDGL - IPHA | 43% Loosely correlated | -1.01% | ||
| ATYR - IPHA | 37% Loosely correlated | -1.33% | ||
| APLM - IPHA | 36% Loosely correlated | +4.75% | ||
| FENC - IPHA | 34% Loosely correlated | -0.58% | ||
| CCXI - IPHA | 34% Loosely correlated | -0.82% | ||
More | ||||